MX363116B - Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata. - Google Patents

Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.

Info

Publication number
MX363116B
MX363116B MX2014015029A MX2014015029A MX363116B MX 363116 B MX363116 B MX 363116B MX 2014015029 A MX2014015029 A MX 2014015029A MX 2014015029 A MX2014015029 A MX 2014015029A MX 363116 B MX363116 B MX 363116B
Authority
MX
Mexico
Prior art keywords
drug conjugates
antibody drug
amino acid
dolastatin analogs
prostate
Prior art date
Application number
MX2014015029A
Other languages
English (en)
Other versions
MX2014015029A (es
Inventor
S Barnett Richard
Tian Feng
A Hays Putnam Anna-Maria
Gymnopoulos Marco
Knudsen Nick
Beck Andrew
Sun Ying
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of MX2014015029A publication Critical patent/MX2014015029A/es
Publication of MX363116B publication Critical patent/MX363116B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a anticuerpos y conjugados anticuerpo-fármaco de antígeno de membrana específico de próstata (PSMA) que comprenden al menos un aminoácido no naturalmente codificado. Se describen en la presente anticuerpos aPSMA con uno o más aminoácidos no naturalmente codificados y se describen además conjugados anticuerpo-fármaco en donde los anticuerpos aPSMA de la invención se conjugan a una o más toxinas. También se describen en la presente análogos de dolastatina de aminoácidos no naturales que se modifican adicionalmente de manera post-traduccional, métodos para efectuar tales modificaciones y métodos para purificar tales análogos de dolastatina. Típicamente, los análogos de dolastatina modificados incluyen al menos un grupo oxima, carbonilo, dicarbonilo y/o hidroxilamina. Además se describen métodos para utilizar tales conjugados anticuerpo-fármaco de aminoácidos no naturales, análogos de dolastatina y análogos de dolastatina de aminoácidos no naturales modificados, incluyendo los usos terapéuticos, de diagnóstico y otros biotecnológicos.
MX2014015029A 2012-06-07 2013-06-07 Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata. MX363116B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656883P 2012-06-07 2012-06-07
PCT/US2013/044850 WO2013185117A1 (en) 2012-06-07 2013-06-07 Prostate-specific membrane antigen antibody drug conjugates

Publications (2)

Publication Number Publication Date
MX2014015029A MX2014015029A (es) 2015-03-03
MX363116B true MX363116B (es) 2019-03-11

Family

ID=48699944

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014015029A MX363116B (es) 2012-06-07 2013-06-07 Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
MX2023010485A MX2023010485A (es) 2012-06-07 2014-12-05 Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
MX2019002732A MX2019002732A (es) 2012-06-07 2014-12-05 Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2023010485A MX2023010485A (es) 2012-06-07 2014-12-05 Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
MX2019002732A MX2019002732A (es) 2012-06-07 2014-12-05 Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.

Country Status (14)

Country Link
US (2) US10800856B2 (es)
EP (2) EP2858676B1 (es)
JP (1) JP6425650B2 (es)
KR (1) KR102143664B1 (es)
CN (3) CN108727466B (es)
AU (2) AU2013270686B2 (es)
CA (1) CA2874854C (es)
DK (1) DK2858676T3 (es)
ES (1) ES2725329T3 (es)
IL (3) IL235895B (es)
MX (3) MX363116B (es)
NZ (2) NZ713941A (es)
SG (2) SG10201702176XA (es)
WO (1) WO2013185117A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013003522B1 (pt) 2010-08-17 2021-05-25 Ambrx, Inc. polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
JP6239597B2 (ja) 2012-05-15 2017-11-29 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 薬物コンジュゲート、コンジュゲーション方法およびその使用
KR102190832B1 (ko) 2012-06-19 2020-12-15 암브룩스, 인코포레이티드 항cd70 항체 약물 컨쥬게이트
JP6431038B2 (ja) 2013-03-15 2018-11-28 ザイムワークス インコーポレイティド 細胞毒性及び抗有糸***性化合物とその使用方法
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
EP3057610B1 (en) 2013-10-15 2021-09-22 Sorrento Therapeutics, Inc. Drug-conjugates with a targeting molecule and two different drugs
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
KR20160125361A (ko) 2013-12-27 2016-10-31 자임워크스 인코포레이티드 Ｖａｒ２ｃｓａ－약물 접합체
SI3134124T1 (sl) 2014-04-25 2019-06-28 Pierre Fabre Medicament Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka
RU2685259C2 (ru) 2014-04-25 2019-04-17 Пьер Фабр Медикамент Конъюгат антитела и лекарственного средства и его применение для лечения рака
HUE057768T2 (hu) 2014-09-17 2022-06-28 Zymeworks Inc Citotoxikus és antimitotikus vegyületek és azok alkalmazásának módszerei
WO2016090050A1 (en) * 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
EP4137159A1 (en) 2015-01-28 2023-02-22 Sorrento Therapeutics, Inc. Antibody drug conjugates
RU2708461C2 (ru) * 2015-02-15 2019-12-09 Цзянсу Хэнжуй Медсин Ко., Лтд. Конъюгат лиганда с цитотоксическим лекарственным средством, способ его получения и применение
TWI715611B (zh) 2015-08-14 2021-01-11 美商Ｒｃ生物科技公司 抗體藥物偶聯物的共價鍵連接子及其製備方法與應用
EP3165532B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Auristatin derivatives, linker-drugs and ligand-drug conjugates
CN114191428A (zh) 2016-03-02 2022-03-18 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
KR102459469B1 (ko) * 2016-11-14 2022-10-26 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
CN110637027A (zh) 2017-02-08 2019-12-31 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
RS65370B1 (sr) 2017-06-02 2024-04-30 Ambrx Inc Metode i kompozicije za unapređenje proizvodnje proteina koji sadrže neprirodne aminokiseline
CN117924503A (zh) 2018-03-29 2024-04-26 Ambrx公司 人源化抗***特异性膜抗原(psma)抗体药物缀合物
CN109232712B (zh) * 2018-08-21 2021-08-03 联宁（苏州）生物制药有限公司 一种用于抗体药物偶联物的中间体的制备方法
CA3076714C (en) * 2019-09-29 2021-06-15 Mabplex International, Ltd. Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof
KR20210095167A (ko) * 2019-09-29 2021-07-30 맙플렉스 인터내셔널 컴퍼니 리미티드 산 방법에 의한 항체-약물 접합체 중간체의 제조 방법 및 이의 적용
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US971A (en) 1838-10-08 Mode of pbeventing dust from rising from threshing-machines when in
US7850A (en) 1850-12-24 Improvement in the manufacture of starch from maize
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
DE3680924D1 (de) 1985-01-14 1991-09-26 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
EP1062230B1 (en) 1998-03-05 2004-10-13 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DK1456360T3 (en) 2001-04-19 2015-08-31 Scripps Research Inst Methods and Composition for Preparation of Orthogonal TRNA-Aminoacyl-TRNA Synthetase Pairs
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
WO2003024388A2 (en) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
AU2002356844C1 (en) 2001-10-23 2010-03-04 Amgen Fremont Inc. PSMA antibodies and protein multimers
US7642085B2 (en) 2002-12-22 2010-01-05 The Scripps Research Institute Protein arrays
CA2606138A1 (en) 2004-04-19 2005-10-27 Proscan Rx Pharma Prostate cancer diagnosis and treatment
US7517903B2 (en) * 2004-05-19 2009-04-14 Medarex, Inc. Cytotoxic compounds and conjugates
ES2545533T3 (es) 2004-11-01 2015-09-11 The Regents Of The University Of California Composiciones y métodos para modificación de biomoléculas
CN101341118A (zh) * 2004-12-22 2009-01-07 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
DK1828224T3 (en) * 2004-12-22 2016-07-18 Ambrx Inc Compositions containing, methods including, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES
CA2598454C (en) 2005-02-18 2013-04-09 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
US8067006B2 (en) * 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
CN101355928B (zh) * 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
CN103127523A (zh) * 2005-06-20 2013-06-05 Psma开发有限公司 Psma抗体-药物缀合物
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
MX2009006617A (es) * 2006-12-18 2009-07-24 Ambrx Inc Composiciones que contienen, metodos que involucran y usos de aminoacidos y polipeptidos no naturales.
PL2326350T3 (pl) * 2008-09-08 2014-03-31 Psma Dev Company L L C Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych
EP3216800A1 (en) * 2008-09-26 2017-09-13 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
WO2012166559A1 (en) * 2011-05-27 2012-12-06 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
CA2837586C (en) * 2011-05-27 2018-12-11 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates

Also Published As

Publication number Publication date
AU2017200877A1 (en) 2017-03-02
IL258937A (en) 2018-06-28
SG11201408153YA (en) 2015-01-29
IL268538A (en) 2019-09-26
CN108727466A (zh) 2018-11-02
CN104619349A (zh) 2015-05-13
AU2017200877B2 (en) 2018-08-30
IL235895A0 (en) 2015-01-29
EP2858676B1 (en) 2019-03-13
KR20150023563A (ko) 2015-03-05
AU2013270686B2 (en) 2016-11-10
MX2019002732A (es) 2023-02-23
EP2858676A1 (en) 2015-04-15
IL268538B (en) 2020-11-30
US10800856B2 (en) 2020-10-13
MX2014015029A (es) 2015-03-03
NZ703298A (en) 2016-04-29
JP6425650B2 (ja) 2018-11-21
MX2023010485A (es) 2023-09-18
NZ713941A (en) 2017-02-24
IL258937B (en) 2019-08-29
IL235895B (en) 2018-05-31
WO2013185117A1 (en) 2013-12-12
CA2874854A1 (en) 2013-12-12
AU2013270686A1 (en) 2015-01-22
CN104619349B (zh) 2018-07-10
CA2874854C (en) 2023-03-14
EP3536700A1 (en) 2019-09-11
US20220033518A1 (en) 2022-02-03
SG10201702176XA (en) 2017-04-27
CN116514899A (zh) 2023-08-01
US20150152190A1 (en) 2015-06-04
CN108727466B (zh) 2023-04-28
DK2858676T3 (da) 2019-05-13
ES2725329T3 (es) 2019-09-23
KR102143664B1 (ko) 2020-08-11
JP2015521590A (ja) 2015-07-30

Similar Documents

Publication Publication Date Title
NZ703298A (en) Prostate-specific membrane antigen antibody drug conjugates
MX359449B (es) Conjugados de anticuerpo fármaco anti-cd70.
MX2013013683A (es) Composiciones que contienen, metodos que involucran, y usos de derivados de dolastatina unidos a aminoacidos no naturales.
SG195183A1 (en) Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
TN2014000120A1 (en) Cd27l antigen binding proteins
WO2013120628A8 (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2015031673A3 (en) Cns-targetedconjugates of antibodies
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
MX371442B (es) VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
MX361728B (es) Ácido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilación para incrementar la expresión de un antígeno tumoral codificado.
EP4276180A3 (en) Clostridium histolyticum enzyme
MY172458A (en) Therapeutic agent or prophylactic agent for dementia
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
NZ724828A (en) Nucleophilic catalysts for oxime linkage
GB2496801A (en) A method of treating alzheimer's disease
WO2013177593A3 (en) Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
EA201300128A1 (ru) Комбинированная фармацевтическая композиция и способы лечения заболеваний или состояний, связанных с нарушением функции сердечно-сосудистой системы
WO2014111840A3 (en) Peptide
WO2010094981A3 (en) Antibody therapy
WO2009071276A3 (de) Allel- und isotyp-spezifische intervention an mit autoimmunerkrankungen assoziierten mhc-klasse-ii-molekülen durch peptide
UA99801C2 (ru) Белковая конструкция, которая включает модифицированный полипептид casb7439
WO2012172151A3 (es) PÉPTIDO ANTIGÉNICO AISLADO DERIVADO DE LA PROTEíNA S100-BETA, PROCEDIMIENTO DE IDENTIFICACiÓN Y SU USO EN LA PREVENCiÓN, TRATAMIENTO, DIAGNÓSTICO Y/O SEGUIMIENTO DE LA DIABETES TIPO 1
EA202090685A1 (ru) Нуклеофильные катализаторы для оксимного связывания